Leuprorelin/norethisterone acetate
Combination of
LeuprorelinGonadotropin-releasing hormone agonist
Norethisterone acetateProgestin
Clinical data
Trade namesLupaneta Pack
Other namesLeuprolide/norethindrone acetate
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration
Intramuscular and by mouth
ATC code
  • None
Legal status
Legal status

Leuprorelin/norethisterone acetate, also known as leuprolide/norethindrone acetate and sold under the brand name Lupaneta Pack, is a co-packaged medication used to treat endometriosis.[1] It contains leuprorelin as the acetate, a gonadotropin-releasing hormone agonist, and norethisterone acetate, a progestin.[1] The leuprorelin is given by intramuscular injection and the norethisterone acetate is taken by mouth.[1]

The co-packaged medication was approved for medical use in the United States in December 2012.[2]

Medical uses

Leuprorelin/norethisterone acetate is indicated for the initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms.[1]

References

  1. 1 2 3 4 5 "Lupaneta Pack (leuprolide acetate for depot suspension; norethindrone acetate tablets), co-packaged for intramuscular use and for oral use, respectively Initial U.S. Approval: 2012". DailyMed. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
  2. "Drug Approval Package: Lupaneta Pack (leuprolide acetate for depot suspension and norethindrone acetate) NDA #203696". U.S. Food and Drug Administration (FDA). 9 September 2013. Archived from the original on 5 April 2021. Retrieved 1 February 2023.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.